ps88 casino download
ps88 casino download
NAIROBI, Kenya -- Three African politicians seeking to head the African Union detailed their plans on Friday for regional security amid conflicts and political coups while strongly advocating for inter-Africa trade among other issues. Raila Odinga of Kenya, Mahamoud Ali Youssouf of Djibouti and Richard Randriamandrato of Madagascar are seeking to be elected as chairperson for the 55-member state African Union. They participated in a two-hour debate Friday in Ethiopian capital Addis Ababa in which they all advocated for two permanent seats for African countries in the U.N. Security Council to effectively represent the continent with the youngest population. Odinga said that two permanent seats with veto power were “a must for Africa” and that this was “only fair” since the continent has more than 50 countries. Randriamandrato urged member states to cease the opportunity and “speak with one voice on the choice of who will represent Africa in the UNSC.” The three are seeking to convince most African countries before the February election to succeed African Union Chairperson Moussa Faki, who has served for two terms. The African Union has faced several challenges that include conflict in member countries and political coups that have seen five member states expelled from the union, making regional security a major theme in Friday’s debate. Youssouf said that regional security could be enhanced if the resources for a regional standby force were increased to reduce the overreliance on foreign partnerships for resources. “When there is no unity of purpose among neighboring countries peace will be compromised,” Youseff said. Randriamandrato encouraged countries to take charge of their internal security while cautioning that foreign military bases should be “a thing of the past” because they “could be a source of conflict.” Despite the continent’s young population of 1.3 billion that is set to double by 2050, regional trade has faced challenges that were addressed in the Friday debate. Odinga said that Africa had a “huge domestic market” that it could leverage on for economic transformation by opening up opportunities for trade between African countries. Youssouf proposed a payment compensation system that would ensure countries don't lose out while trading in different currencies adding, “are we going to have a single currency, why not?” Randriamandrato said that regional economic blocs like the Common Market for Eastern and Southern Africa had a huge role to play in easing inter-Africa trade. The African Union has several proposed reforms on its structure and leadership aimed at achieving its purpose, and all candidates promised to implement the reforms if elected. Youssouf said that key reforms in the union were facing a funding bottleneck and that “it has to change,” adding that he wouldn't impose it on member states but would “advocate for it.”Chuck Woolery Dies: Former ‘Wheel of Fortune’ and ‘Love Connection’ Host Was 83None
VANCOUVER — The British Columbia New Democrats have negotiated a deal with the two Green Party members of the legislature that will help stabilize the New Democrats' slim majority government, Premier David Eby says. The premier said in a statement Friday that while the two parties are distinct and won't always agree, they have "many shared values." Eby's party won a bare majority with 47 seats in the October provincial election, while two Greens were elected and the B.C. Conservatives have 44 seats. He said the deal sets out specific areas of action they'll work together to achieve, which includes health care, affordable housing, creating livable communities and growing a strong, sustainable economy. "This agreement will strengthen the stability of government and help deliver on the priorities of British Columbians. We will continue to work with all MLAs who want to make the legislature work for people," Eby said. The stability of the NDP government got even shakier earlier this month when New Democrat Grace Lore announced she had cancer and was stepping away from her role as children's minister. B.C. Conservative Party Leader John Rustad has said he would work to bring the NDP government down if it continues with its "destructive policies." This report by The Canadian Press was first published Dec. 13, 2024. Brenna Owen, The Canadian Press
Longview (10-2) vs. Klein Collins (7-5) Time : 2 p.m. Saturday Stadium : Abe Martin Stadium, 309 South Medford Drive, Lufkin, 75901 Coaches : Longview: John King; Klein Collins: Adrian Mitchell WHEN LONGVIEW HAS THE BALL Players to Watch Longview : Kelvin Washington (1,907 rushing yards, 353 receiving yards, 24 rushing touchdowns, and six receiving touchdowns this season) ... Maverick Rowe (1,020 passing yards, 223 rushing yards, 13 passing touchdowns, and two rushing touchdowns) ... Buster Mumphrey (395 rushing yards, 80 receiving yards, two rushing touchdowns, and one receiving touchdown) ... Johnny Hamilton (289 passing yards, 41 rushing yards, and four passing touchdowns) ...Da’Morrion Williams (240 receiving yards and four receiving touchdowns) ... Mason Washington (207 rushing yards and 22 receiving yards) ... Jaden Hurndon (186 receiving yards, 24 rushing yards, and one receiving touchdown) ... Kieffer Doxey (137 receiving yards and one rushing yard) ... Javarion Pereira (115 rushing yards and one rushing touchdown) ... Jace Peterson (95 receiving yards and one receiving touchdown) Klein Collins : Larry Hankton (interception in last Friday’s 70-21 win against The Woodlands College Park) ... Gavin Dartez ... Jarrod Penright ... Jose Eljach ... Luis Vasquez ... Trent Spence ... JD Brady ... Christian Wilkerson ... Randall Jackson ... Gabriel Gomez Keys : Longview continues to have two viable options at the quarterback position in normal starter Maverick Rowe and a regular backup in Johnny Hamilton that guided the team to a come-from-behind overtime win against Lancaster in a rare start last Friday. Regardless of who sees the most action under center this week, the Lobos’ offensive unit needs to focus on scoring and taking advantage of a Klein Collins’ defense that has allowed 27.3 points per game to opponents this year. Luckily for Longview, it has enough threats in versatile offensive statistical leader Kelvin Washington, rushing talents Buster Mumphrey, Mason Washington and Javarion Pereira, and receivers Da’Morrion Williams, Jaden Hurndon, Kieffer Doxey and Jace Peterson to build on its 31.2 points per game average this year. Klein Collins will attempt to slow those players down with defensive standouts like Larry Hankton, Gavin Dartez, Jarrod Penright, Jose Eljach, Luis Vasquez, Trent Spence, JD Brady, Christian Wilkerson, Randall Jackson and Gabriel Gomez. WHEN KLEIN COLLINS HAS THE BALL Players to Watch Klein Collins : Braydon Schoggin (multiple rushing touchdowns in last Friday’s 70-21 win against The Woodlands College Park) ... Carlton Hayden (rushing touchdown last week) ... Brice Romero (rushing touchdown last week)... Jeremiah Hutching ... Kajuan Gathers ... Jai’Shaun Jackson ... Brandon Dujay ... Gabriel Gomez ... Eddie Lartigue ... Randall Jackson Longview : Kason Brooks (132 tackles, 31 tackles for loss, 13 sacks, three touchdowns, two pass breakups, one interception, one forced fumble, and one fumble recovery this season) ... Jamayis Morrow (122 tackles, five tackles for loss, three forced fumbles, two fumble recoveries, two pass breakups, and one sack) ... Brenden Reese (106 tackles, 18 tackles for loss, five sacks, two pass breakups, one interception, and one forced fumble) ... Bryan Peoples (80 tackles, four pass breakups, three tackles for loss, two interceptions, and one forced fumble) ... Da’Kayden Carter (52 tackles, six pass breakups, two interceptions, and one forced fumble) ... Jessier Hampton-Williams (43 tackles, six tackles for loss, three sacks, one pass breakup, one forced fumble, and one touchdown) ... Bradley Williams (43 tackles, three pass breakups, two fumble recoveries, and one interception) ... Robert White (41 tackles, seven pass breakups, and one tackle for loss) ... Jailynn Taylor (36 tackles, six pass breakups, and three interceptions) ...Jaden Woolridge (34 tackles and five tackles for loss) Keys : Klein Collins’ high-powered offense has even caught the attention of Longview’s show-stopping defense, so an eye-popping matchup is in store this week. The Tigers eliminated The Woodlands College Park with a 70-point scoring outburst last Friday, and has leaned on an offensive unit that’s averaged 32 points per game this season. The group will lean on a rushing attack that features Braydon Schoggin, Carlton Hayden and Brice Romero, and other offensive assets like Jeremiah Hutching, Kajuan Gathers, Jai’Shaun Jackson, Brandon Dujay, Gabriel Gomez, Eddie Lartigue and Randall Jackson. Longview’s defensive unit, meanwhile, has limited its first 12 opponents to only 16.5 points per game this season and shut out early November opponents North Forney and Royse City. The Lobos have the necessary leaders in Kason Brooks, Jamayis Morrow, Brenden Reese, Bryan Peoples, Da’Kayden Carter, Jessier Hampton-Williams, Bradley Williams, Robert White, Jailynn Taylor and Jaden Woolridge to counter this week’s foe, and fill in for an injured standout teammate in Isaiah Horton (74 tackles, 21 tackles for loss, 10 sacks, one fumble recovery, and one touchdown in 11 games in 2024) that will miss the remainder of the season according to Longview head coach John King. Did You Know : Longview has produced an 82-46-1 playoff record during its 50 postseason appearances since 1924 ... The Lobos will bring an 11-7 regional semifinal record to their 19th trip since 1975 ... Klein Collins has earned an 18-15 postseason record during its 16 playoff appearances since 2004 ... The Tigers own a 1-4 regional semifinal record before their sixth trip since 2009 ... Longview and Klein Collins will meet in the UIL 6A Division II Region II semifinal round for the second time ... The Lobos lead the all-time football series 1-0 after a 30-24 win against the Tigers at Waco’s McLane Stadium on Dec. 2, 2017. Last Week : Longview 35, Lancaster 28 (OT); Klein Collins 70, The Woodlands College Park 21 Up Next : Winner plays DeSoto or Willis THOMAS BINGHAMThe year in money: inflation eased, optimism ticked upwardNone
Financing faceoff: Can Lind get his grand project past government goaltenders?
COLORADO 73, NO. 2 UCONN 72RumbleOn Announces Commencement of $10.0 Million Fully Backstopped Registered Rights Offering
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL) 1 Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems 1 These encouraging five-year results continue to highlight the potential of this Polivy combination to improve outcomes in first-line DLBCL, an area that previously had little advancement in nearly two decades Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, 7-10 December 2024 in San Diego, US. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. 1 “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favour of Polivy in combination with R-CHP compared to MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. 1 “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, MD, PhD, Chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, US. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% vs 61.7%). 1 Based on findings from a previous economic analysis which found that total healthcare costs increased with each additional line of treatment in relapsed or refractory DLBCL, a reduction in the number of subsequent therapies could potentially alleviate some of the burdens associated with relapse and disease progression. 2 At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% vs 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. 1 Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. 1 Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the US, countries throughout the EU, the UK, Japan, Canada and China. Roche continues to work with health authorities around the world to bring this treatment regimen to even more patients. Roche aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Roche is exploring Polivy in combination with other molecules including its bispecific antibodies. Studies include the phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio® (mosunetuzumab) in combination with intravenous (IV) Polivy versus IV MabThera/Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi® (glofitamab) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX study POLARIX [ NCT03274492 ] is an international phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy® (polatuzumab vedotin) plus MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomised 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by MabThera/Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of MabThera/Rituxan. The primary outcome measure is progression-free survival (PFS) as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. PFS is a clinically meaningful disease-related outcome for patients with previously untreated DLBCL as it represents the goal of first-line therapy: decreasing the risk of disease worsening. Overall survival is a secondary endpoint in the POLARIX study. About diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for about one in three cases of NHL. 3 DLBCL is an aggressive (fast-growing) type of NHL. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. 4,5 Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes. Approximately 160,000 people worldwide are estimated to be diagnosed with DLBCL each year. 1,6 About Polivy® (polatuzumab vedotin) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B-cells through the delivery of an anti-cancer agent, which is thought to minimise the effects on normal cells. Polivy is being developed by Roche using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. About Roche in haematology Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera/Rituxan, Gazyva®/Gazyvaro® (obinutuzumab), Polivy, Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com . All trademarks used or mentioned in this release are protected by law. References [1] Gilles S, et al. Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes. Presented at: ASH Annual Meeting and Exposition; 2024 Dec 7-10; San Diego, CA, USA. Abstract #469. [2] Gatwood J, et al. Total cost of care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Presented at: ASH Annual Meeting and Exposition; 2022, Dec 10-13. Abstract #3527 [3] Cancer.Net. Lymphoma - Non-Hodgkin: Subtypes. [Internet; cited December 2024]. Available from: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes [4] Sehn LH, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. [5] Maurer MJ, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066-73. [6] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited December 2024]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pd . Dr. Salles has financial interests related to Roche and Genentech. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Roche Investor Relations Investor Relations North America Attachment 08122024_POLARIX 5-year data_en
Computer modeling shows close encounters between distant DNA regions cause bursts of gene activity
Elon Musk was asked at the recent SpaceX launch if he played League of Legends, to which he said if he did, it "would damage the space program". At the recent SpaceX launch, President-elect Trump and members of his family were in attendance hanging around with the Tesla, SpaceX and now DOGE boss asking him some space-related questions, but then the questions moved to gaming as they Elon is a gamer. The group were talking about the difficulties of getting into space and blasting off to Mars, when Elon was asked: " what's harder, this or Greater Rifts in Diablo 4 ". Elon laughs, but then Kai Trump asks Elon if ever played Fortnite, to which he replied " no, but I did like Quake and a bunch of other first-person shooters ". He was then asked " League, did you play League (of Legends) ". Elon said about playing League: " League... if I started playing League, it will damage the space program ". Elon has a great sense of humor, as he knows a game like League of Legends would time suck his life away, even more than the time he pumps into being a global top 20 player in Diablo 4.
College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama outUnwrap the latest AI features with Amazon Fire Tablets
Caitlin Clark joins Cincinnati’s bid for 16th NWSL teamJonah Goldberg: What if most Americans aren't bitterly divided?Daily Post Nigeria NPFL: Niger Tornadoes coach reflects on draw against Ikorodu City Home News Politics Metro Entertainment Sport Sport NPFL: Niger Tornadoes coach reflects on draw against Ikorodu City Published on November 24, 2024 By Taiwo Adesanya Niger Tornadoes technical adviser, Majin Mohammed has blamed missed chances for his team’s goalless draw against Ikorodu City. The Ikon Allah Boys were held to a goalless draw by Ikorodu City at the Bako Kontagora Stadium , Minna, on Saturday. Mohammed however acknowledged Ikorodu City’s impressive run of form in the league. “We created chances, but failed to capitalize,” Mohammed told Niger Tornadoes media. “Ikorodu City are not a bad side, they picked form since their present coach took over the team and ever since have been doing well. “I think they’ve lost just once in so many games, but that doesn’t mean they are not beatable, in fact the story would have been different if we took our chances.” Related Topics: Ikorodu City Niger Tornadoes NPFL Don't Miss EPL: Amorim includes 16-year-old defender in Man Utd squad to face Ipswich You may like NPFL announces new kick-off time for Plateau United vs Nasarawa United NPFL: Niger Tornadoes going for victory against Ikorodu City — Mohammed NPFL, Enyimba want domestic, continental glory – Olanrewaju NPFL: Oriental derby with Rangers a ‘brotherly affair’ — Heartland coach, Uzor NPFL: Odigie’s resignation won’t affect Bendel Insurance – Oronsanye NPFL: Ikorodu City city star Abdulmalik satisfied with maiden campaign Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd
UCF 80, Florida A&M 55
( ) has dived after a new breakout attempt past a 484.82 and triggered a . Let's consider a short iron condor trade in Berkshire Hathaway stock. When we position with short iron condors, we attempt to collect time decay while a stock on its chart or settles into a new direction. As always, we assume that we don't know the direction. But we estimate the magnitude of the move using (average true range, as measured on the monthly chart in this instance). We also gauge the implied moves that market makers have priced into the stock in the months ahead. , Berkshire Hathaway stock holds a 65 , down from 83 three months ago. Berkshire Hathaway Stock: The Trade The short iron condor consists of two spreads: a short call spread and a short put spread. These two price spreads define a range of motion that we estimate the price action in Berkshire Hathaway stock will not exceed. Let's set up the trade as follows: Stock hunting using fundamental and price strength is where I firmly plant myself under the current economic backdrop. I use to find ideal buying opportunities in conjunction with the tools for strength seen on IBD.
Smartphone brands might not opt for Snapdragon 8 Elite 2 in 2025, Know why
ps88 casino download
NAIROBI, Kenya -- Three African politicians seeking to head the African Union detailed their plans on Friday for regional security amid conflicts and political coups while strongly advocating for inter-Africa trade among other issues. Raila Odinga of Kenya, Mahamoud Ali Youssouf of Djibouti and Richard Randriamandrato of Madagascar are seeking to be elected as chairperson for the 55-member state African Union. They participated in a two-hour debate Friday in Ethiopian capital Addis Ababa in which they all advocated for two permanent seats for African countries in the U.N. Security Council to effectively represent the continent with the youngest population. Odinga said that two permanent seats with veto power were “a must for Africa” and that this was “only fair” since the continent has more than 50 countries. Randriamandrato urged member states to cease the opportunity and “speak with one voice on the choice of who will represent Africa in the UNSC.” The three are seeking to convince most African countries before the February election to succeed African Union Chairperson Moussa Faki, who has served for two terms. The African Union has faced several challenges that include conflict in member countries and political coups that have seen five member states expelled from the union, making regional security a major theme in Friday’s debate. Youssouf said that regional security could be enhanced if the resources for a regional standby force were increased to reduce the overreliance on foreign partnerships for resources. “When there is no unity of purpose among neighboring countries peace will be compromised,” Youseff said. Randriamandrato encouraged countries to take charge of their internal security while cautioning that foreign military bases should be “a thing of the past” because they “could be a source of conflict.” Despite the continent’s young population of 1.3 billion that is set to double by 2050, regional trade has faced challenges that were addressed in the Friday debate. Odinga said that Africa had a “huge domestic market” that it could leverage on for economic transformation by opening up opportunities for trade between African countries. Youssouf proposed a payment compensation system that would ensure countries don't lose out while trading in different currencies adding, “are we going to have a single currency, why not?” Randriamandrato said that regional economic blocs like the Common Market for Eastern and Southern Africa had a huge role to play in easing inter-Africa trade. The African Union has several proposed reforms on its structure and leadership aimed at achieving its purpose, and all candidates promised to implement the reforms if elected. Youssouf said that key reforms in the union were facing a funding bottleneck and that “it has to change,” adding that he wouldn't impose it on member states but would “advocate for it.”Chuck Woolery Dies: Former ‘Wheel of Fortune’ and ‘Love Connection’ Host Was 83None
VANCOUVER — The British Columbia New Democrats have negotiated a deal with the two Green Party members of the legislature that will help stabilize the New Democrats' slim majority government, Premier David Eby says. The premier said in a statement Friday that while the two parties are distinct and won't always agree, they have "many shared values." Eby's party won a bare majority with 47 seats in the October provincial election, while two Greens were elected and the B.C. Conservatives have 44 seats. He said the deal sets out specific areas of action they'll work together to achieve, which includes health care, affordable housing, creating livable communities and growing a strong, sustainable economy. "This agreement will strengthen the stability of government and help deliver on the priorities of British Columbians. We will continue to work with all MLAs who want to make the legislature work for people," Eby said. The stability of the NDP government got even shakier earlier this month when New Democrat Grace Lore announced she had cancer and was stepping away from her role as children's minister. B.C. Conservative Party Leader John Rustad has said he would work to bring the NDP government down if it continues with its "destructive policies." This report by The Canadian Press was first published Dec. 13, 2024. Brenna Owen, The Canadian Press
Longview (10-2) vs. Klein Collins (7-5) Time : 2 p.m. Saturday Stadium : Abe Martin Stadium, 309 South Medford Drive, Lufkin, 75901 Coaches : Longview: John King; Klein Collins: Adrian Mitchell WHEN LONGVIEW HAS THE BALL Players to Watch Longview : Kelvin Washington (1,907 rushing yards, 353 receiving yards, 24 rushing touchdowns, and six receiving touchdowns this season) ... Maverick Rowe (1,020 passing yards, 223 rushing yards, 13 passing touchdowns, and two rushing touchdowns) ... Buster Mumphrey (395 rushing yards, 80 receiving yards, two rushing touchdowns, and one receiving touchdown) ... Johnny Hamilton (289 passing yards, 41 rushing yards, and four passing touchdowns) ...Da’Morrion Williams (240 receiving yards and four receiving touchdowns) ... Mason Washington (207 rushing yards and 22 receiving yards) ... Jaden Hurndon (186 receiving yards, 24 rushing yards, and one receiving touchdown) ... Kieffer Doxey (137 receiving yards and one rushing yard) ... Javarion Pereira (115 rushing yards and one rushing touchdown) ... Jace Peterson (95 receiving yards and one receiving touchdown) Klein Collins : Larry Hankton (interception in last Friday’s 70-21 win against The Woodlands College Park) ... Gavin Dartez ... Jarrod Penright ... Jose Eljach ... Luis Vasquez ... Trent Spence ... JD Brady ... Christian Wilkerson ... Randall Jackson ... Gabriel Gomez Keys : Longview continues to have two viable options at the quarterback position in normal starter Maverick Rowe and a regular backup in Johnny Hamilton that guided the team to a come-from-behind overtime win against Lancaster in a rare start last Friday. Regardless of who sees the most action under center this week, the Lobos’ offensive unit needs to focus on scoring and taking advantage of a Klein Collins’ defense that has allowed 27.3 points per game to opponents this year. Luckily for Longview, it has enough threats in versatile offensive statistical leader Kelvin Washington, rushing talents Buster Mumphrey, Mason Washington and Javarion Pereira, and receivers Da’Morrion Williams, Jaden Hurndon, Kieffer Doxey and Jace Peterson to build on its 31.2 points per game average this year. Klein Collins will attempt to slow those players down with defensive standouts like Larry Hankton, Gavin Dartez, Jarrod Penright, Jose Eljach, Luis Vasquez, Trent Spence, JD Brady, Christian Wilkerson, Randall Jackson and Gabriel Gomez. WHEN KLEIN COLLINS HAS THE BALL Players to Watch Klein Collins : Braydon Schoggin (multiple rushing touchdowns in last Friday’s 70-21 win against The Woodlands College Park) ... Carlton Hayden (rushing touchdown last week) ... Brice Romero (rushing touchdown last week)... Jeremiah Hutching ... Kajuan Gathers ... Jai’Shaun Jackson ... Brandon Dujay ... Gabriel Gomez ... Eddie Lartigue ... Randall Jackson Longview : Kason Brooks (132 tackles, 31 tackles for loss, 13 sacks, three touchdowns, two pass breakups, one interception, one forced fumble, and one fumble recovery this season) ... Jamayis Morrow (122 tackles, five tackles for loss, three forced fumbles, two fumble recoveries, two pass breakups, and one sack) ... Brenden Reese (106 tackles, 18 tackles for loss, five sacks, two pass breakups, one interception, and one forced fumble) ... Bryan Peoples (80 tackles, four pass breakups, three tackles for loss, two interceptions, and one forced fumble) ... Da’Kayden Carter (52 tackles, six pass breakups, two interceptions, and one forced fumble) ... Jessier Hampton-Williams (43 tackles, six tackles for loss, three sacks, one pass breakup, one forced fumble, and one touchdown) ... Bradley Williams (43 tackles, three pass breakups, two fumble recoveries, and one interception) ... Robert White (41 tackles, seven pass breakups, and one tackle for loss) ... Jailynn Taylor (36 tackles, six pass breakups, and three interceptions) ...Jaden Woolridge (34 tackles and five tackles for loss) Keys : Klein Collins’ high-powered offense has even caught the attention of Longview’s show-stopping defense, so an eye-popping matchup is in store this week. The Tigers eliminated The Woodlands College Park with a 70-point scoring outburst last Friday, and has leaned on an offensive unit that’s averaged 32 points per game this season. The group will lean on a rushing attack that features Braydon Schoggin, Carlton Hayden and Brice Romero, and other offensive assets like Jeremiah Hutching, Kajuan Gathers, Jai’Shaun Jackson, Brandon Dujay, Gabriel Gomez, Eddie Lartigue and Randall Jackson. Longview’s defensive unit, meanwhile, has limited its first 12 opponents to only 16.5 points per game this season and shut out early November opponents North Forney and Royse City. The Lobos have the necessary leaders in Kason Brooks, Jamayis Morrow, Brenden Reese, Bryan Peoples, Da’Kayden Carter, Jessier Hampton-Williams, Bradley Williams, Robert White, Jailynn Taylor and Jaden Woolridge to counter this week’s foe, and fill in for an injured standout teammate in Isaiah Horton (74 tackles, 21 tackles for loss, 10 sacks, one fumble recovery, and one touchdown in 11 games in 2024) that will miss the remainder of the season according to Longview head coach John King. Did You Know : Longview has produced an 82-46-1 playoff record during its 50 postseason appearances since 1924 ... The Lobos will bring an 11-7 regional semifinal record to their 19th trip since 1975 ... Klein Collins has earned an 18-15 postseason record during its 16 playoff appearances since 2004 ... The Tigers own a 1-4 regional semifinal record before their sixth trip since 2009 ... Longview and Klein Collins will meet in the UIL 6A Division II Region II semifinal round for the second time ... The Lobos lead the all-time football series 1-0 after a 30-24 win against the Tigers at Waco’s McLane Stadium on Dec. 2, 2017. Last Week : Longview 35, Lancaster 28 (OT); Klein Collins 70, The Woodlands College Park 21 Up Next : Winner plays DeSoto or Willis THOMAS BINGHAMThe year in money: inflation eased, optimism ticked upwardNone
Financing faceoff: Can Lind get his grand project past government goaltenders?
COLORADO 73, NO. 2 UCONN 72RumbleOn Announces Commencement of $10.0 Million Fully Backstopped Registered Rights Offering
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL) 1 Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems 1 These encouraging five-year results continue to highlight the potential of this Polivy combination to improve outcomes in first-line DLBCL, an area that previously had little advancement in nearly two decades Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition, 7-10 December 2024 in San Diego, US. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. 1 “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favour of Polivy in combination with R-CHP compared to MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. 1 “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, MD, PhD, Chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, US. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% vs 61.7%). 1 Based on findings from a previous economic analysis which found that total healthcare costs increased with each additional line of treatment in relapsed or refractory DLBCL, a reduction in the number of subsequent therapies could potentially alleviate some of the burdens associated with relapse and disease progression. 2 At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% vs 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. 1 Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. 1 Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the US, countries throughout the EU, the UK, Japan, Canada and China. Roche continues to work with health authorities around the world to bring this treatment regimen to even more patients. Roche aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Roche is exploring Polivy in combination with other molecules including its bispecific antibodies. Studies include the phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio® (mosunetuzumab) in combination with intravenous (IV) Polivy versus IV MabThera/Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi® (glofitamab) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX study POLARIX [ NCT03274492 ] is an international phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy® (polatuzumab vedotin) plus MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomised 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by MabThera/Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of MabThera/Rituxan. The primary outcome measure is progression-free survival (PFS) as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. PFS is a clinically meaningful disease-related outcome for patients with previously untreated DLBCL as it represents the goal of first-line therapy: decreasing the risk of disease worsening. Overall survival is a secondary endpoint in the POLARIX study. About diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for about one in three cases of NHL. 3 DLBCL is an aggressive (fast-growing) type of NHL. While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short. 4,5 Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes. Approximately 160,000 people worldwide are estimated to be diagnosed with DLBCL each year. 1,6 About Polivy® (polatuzumab vedotin) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B-cells, an immune cell impacted in some types of non-Hodgkin lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B-cells through the delivery of an anti-cancer agent, which is thought to minimise the effects on normal cells. Polivy is being developed by Roche using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. About Roche in haematology Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera/Rituxan, Gazyva®/Gazyvaro® (obinutuzumab), Polivy, Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3 and Tecentriq® (atezolizumab). Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com . All trademarks used or mentioned in this release are protected by law. References [1] Gilles S, et al. Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes. Presented at: ASH Annual Meeting and Exposition; 2024 Dec 7-10; San Diego, CA, USA. Abstract #469. [2] Gatwood J, et al. Total cost of care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Presented at: ASH Annual Meeting and Exposition; 2022, Dec 10-13. Abstract #3527 [3] Cancer.Net. Lymphoma - Non-Hodgkin: Subtypes. [Internet; cited December 2024]. Available from: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes [4] Sehn LH, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. [5] Maurer MJ, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066-73. [6] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited December 2024]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pd . Dr. Salles has financial interests related to Roche and Genentech. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Roche Investor Relations Investor Relations North America Attachment 08122024_POLARIX 5-year data_en
Computer modeling shows close encounters between distant DNA regions cause bursts of gene activity
Elon Musk was asked at the recent SpaceX launch if he played League of Legends, to which he said if he did, it "would damage the space program". At the recent SpaceX launch, President-elect Trump and members of his family were in attendance hanging around with the Tesla, SpaceX and now DOGE boss asking him some space-related questions, but then the questions moved to gaming as they Elon is a gamer. The group were talking about the difficulties of getting into space and blasting off to Mars, when Elon was asked: " what's harder, this or Greater Rifts in Diablo 4 ". Elon laughs, but then Kai Trump asks Elon if ever played Fortnite, to which he replied " no, but I did like Quake and a bunch of other first-person shooters ". He was then asked " League, did you play League (of Legends) ". Elon said about playing League: " League... if I started playing League, it will damage the space program ". Elon has a great sense of humor, as he knows a game like League of Legends would time suck his life away, even more than the time he pumps into being a global top 20 player in Diablo 4.
College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama outUnwrap the latest AI features with Amazon Fire Tablets
Caitlin Clark joins Cincinnati’s bid for 16th NWSL teamJonah Goldberg: What if most Americans aren't bitterly divided?Daily Post Nigeria NPFL: Niger Tornadoes coach reflects on draw against Ikorodu City Home News Politics Metro Entertainment Sport Sport NPFL: Niger Tornadoes coach reflects on draw against Ikorodu City Published on November 24, 2024 By Taiwo Adesanya Niger Tornadoes technical adviser, Majin Mohammed has blamed missed chances for his team’s goalless draw against Ikorodu City. The Ikon Allah Boys were held to a goalless draw by Ikorodu City at the Bako Kontagora Stadium , Minna, on Saturday. Mohammed however acknowledged Ikorodu City’s impressive run of form in the league. “We created chances, but failed to capitalize,” Mohammed told Niger Tornadoes media. “Ikorodu City are not a bad side, they picked form since their present coach took over the team and ever since have been doing well. “I think they’ve lost just once in so many games, but that doesn’t mean they are not beatable, in fact the story would have been different if we took our chances.” Related Topics: Ikorodu City Niger Tornadoes NPFL Don't Miss EPL: Amorim includes 16-year-old defender in Man Utd squad to face Ipswich You may like NPFL announces new kick-off time for Plateau United vs Nasarawa United NPFL: Niger Tornadoes going for victory against Ikorodu City — Mohammed NPFL, Enyimba want domestic, continental glory – Olanrewaju NPFL: Oriental derby with Rangers a ‘brotherly affair’ — Heartland coach, Uzor NPFL: Odigie’s resignation won’t affect Bendel Insurance – Oronsanye NPFL: Ikorodu City city star Abdulmalik satisfied with maiden campaign Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd
UCF 80, Florida A&M 55
( ) has dived after a new breakout attempt past a 484.82 and triggered a . Let's consider a short iron condor trade in Berkshire Hathaway stock. When we position with short iron condors, we attempt to collect time decay while a stock on its chart or settles into a new direction. As always, we assume that we don't know the direction. But we estimate the magnitude of the move using (average true range, as measured on the monthly chart in this instance). We also gauge the implied moves that market makers have priced into the stock in the months ahead. , Berkshire Hathaway stock holds a 65 , down from 83 three months ago. Berkshire Hathaway Stock: The Trade The short iron condor consists of two spreads: a short call spread and a short put spread. These two price spreads define a range of motion that we estimate the price action in Berkshire Hathaway stock will not exceed. Let's set up the trade as follows: Stock hunting using fundamental and price strength is where I firmly plant myself under the current economic backdrop. I use to find ideal buying opportunities in conjunction with the tools for strength seen on IBD.
Smartphone brands might not opt for Snapdragon 8 Elite 2 in 2025, Know why
-
">
-
"> -
"> -
">
